Skip to main content

Table 3 The expected savings and QALYs gained on an individual and population level among 100,399 women and 80,375 men in non-T2D pharmacy visiting population. Comparator for the intervention was current practice

From: Pharmacy-based screening to detect persons at elevated risk of type 2 diabetes: a cost-utility analysis

 

10-year time period

20-year time period

30-year time period

Women

Men

Women

Men

Women

Men

Expected savings potential per person € (95% CI)

15 (− 799 to 945)

268 (− 799 to 1520)

1031 (− 1002 to 3264)

1889 (− 1053 to 4846)

1457 (− 1085 to 4024)

2115 (− 816 to 5239)

Expected savings potential per person Only direct costs € (95% CI)

− 410 (− 738 to − 39)

− 228 (− 738 to 343)

625 (− 1012 to 2472)

1264 (− 1105 to 3601)

1044 (− 967 to 3107)

1526 (− 1133 to 3920)

Expected gained QALYs per person (95% CI)

0.0031 (−0.0004 to 0.0074)

0.0055 (− 0.0008 to 0.0133)

0.0270 (− 0.0054 to 0.0623)

0.0538 (− 0.010 to 0.1230)

0.0684 (− 0.0141 to 0.1512)

0.0877 (− 0.0102 to 0.1904)

Expected savings potential, population m€ (95% CI)

1.5 (−80.2 to 94.9)

21.5 (−64.3 to 122.1)

103.5 (− 100.5 to 327.7)

151.8 (− 84.7 to 389.5)

146.2 (− 108.9 to 404.0)

170.0 (− 65.6 to 421.1)

Expected savings potential, population Only direct costs m€ (95% CI)

− 41.2 (− 74.1 to − 3.9)

−18.3 (− 59.4 to 27.6)

62.7 (− 101.6 to 248.2)

101.6 (− 88.8 to 289.4)

104.9 (− 97.1 to 312.0)

122.9 (− 91.1 to 315.0)

Expected gained QALYs, population (95% CI)

309 (−43 to 738)

445 (−61 to 1068)

2712 (− 540 to 6257)

4320 (− 804 to 9886)

6869 (− 1418 to 15,178)

8979 (− 435 to 19,239)

Net monetary benefit, cost-effectiveness threshold of 50,000 €/QALY (€) (95% CI)

170 (− 819 to 1315)

543 (− 839 to 2185)

2381 (− 1272 to 6379)

4579 (− 1553 to 10,996)

4877 (− 1790 to 11,584)

6500 (− 1326 to 14,759)

  1. CI Confidence interval, QALY Quality-adjusted life year